PMC7646409_01
Histopathologic stains from the pulmonary biopsy. (A) hematoxylin and eosin. (B) CK5/6 (C) CK7. (D) thyroid transcription factor-1. (E) Naspin A. (F) P63. (G) P40. (H) Ki67. (x400). cytokeratin (CK).
OTT-13-11177-g0001.jpg
PMC7646409_01_OTT-13-11177-g0001.jpg
f0001
The immunohistochemistry staining results of pulmonary biopsy were CK5/6-positive, CK7-positive, thyroid transcription factor-1-positive, Naspin A-negative, P63-negative, P40-negative and Ki-67 positive index 30% (Figure 1).
Next-generation sequencing findings of MYH9-RET fusion. (A) The Integrative Genomics Viewer snapshot of MYH9-RET. (B) Schematic representation of the MYH9-RET fusion protein domain structure.
OTT-13-11177-g0002.jpg
PMC7646409_01_OTT-13-11177-g0002.jpg
f0002
EGFR exon19 p. E746_A750del, EGFR amplification as well as a novel MYH9 (exon41)-RET (exon12) fusion (Figure 2) were identified, without EGFR exon20 p.T790M.
Computed tomography (CT) scan detecting and treatment course. (A-E) Chest CT scans showed the effects of different types of therapy of the patient's lung tumor. (F) Time line of the patient accepting treatments and duration of every treatment.
OTT-13-11177-g0003.jpg
PMC7646409_01_OTT-13-11177-g0003.jpg
f0003
The findings of gene sequencing during treatment were given in Table 1 and time line of the treatments and the effects of different types of therapy were presented in Figure 3.